Nabriva Therapeutics plc Ordinary Shares Ireland
NBRV
NBRV was delisted on the 31st of July, 2023.
38 hedge funds and large institutions have $69.1M invested in Nabriva Therapeutics plc Ordinary Shares Ireland in 2019 Q2 according to their latest regulatory filings, with 7 funds opening new positions, 13 increasing their positions, 7 reducing their positions, and 8 closing their positions.
86% more repeat investments, than reductions
Existing positions increased: 13 | Existing positions reduced: 7
28% more call options, than puts
Call options by funds: $272K | Put options by funds: $212K
3% less capital invested
Capital invested by funds: $71.1M → $69.1M (-$1.95M)
3% less funds holding
Funds holding: 39 → 38 (-1)
13% less first-time investments, than exits
New positions opened: 7 | Existing positions closed: 8
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$1.09M |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$660K |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$602K |
| 4 |
Dimensional Fund Advisors
Austin,
Texas
|
+$509K |
| 5 |
Millennium Management
New York
|
+$481K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NHAS
Novo Holdings A/S
Hellerup,
Denmark
|
-$3.08M |
| 2 |
VC
Vivo Capital
Palo Alto,
California
|
-$894K |
| 3 |
Arrowstreet Capital
Boston,
Massachusetts
|
-$578K |
| 4 |
Goldman Sachs
New York
|
-$327K |
| 5 |
Two Sigma Investments
New York
|
-$306K |
NBRV Hedge Fund Activity: Q2 2019 in Review
38 of the 4,605 institutional investors tracked by Wall St. Rank reported a position in Nabriva Therapeutics plc Ordinary Shares Ireland (NBRV) for Q2 2019, worth a combined $69.1M — down 2.7% from $71.1M a quarter earlier.
Sellers outnumbered buyers: 8 funds closed out of NBRV and 7 opened new positions — a net loss of 1 holder — while 7 trimmed existing stakes and 13 added.
The largest buyer was Renaissance Technologies, adding an estimated $1.09M. The largest seller was Novo Holdings A/S, cutting an estimated $3.08M.
- 38 institutional investors held Nabriva Therapeutics plc Ordinary Shares Ireland (NBRV) as of Q2 2019, down from 39 in Q1 2019.
- Funds reported $69.1M of Nabriva Therapeutics plc Ordinary Shares Ireland stock for Q2 2019, down 2.7% quarter-over-quarter.
- 7 funds opened new Nabriva Therapeutics plc Ordinary Shares Ireland positions in Q2 2019 and 8 closed out, a net change of -1 holder.
- The largest Nabriva Therapeutics plc Ordinary Shares Ireland buyer in Q2 2019 was Renaissance Technologies, an estimated $1.09M added.
- The largest Nabriva Therapeutics plc Ordinary Shares Ireland seller in Q2 2019 was Novo Holdings A/S, an estimated $3.08M sold.
Based on aggregated 13F filings for Q2 2019.